Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, Botikov AG, Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Egorova DA, Shmarov MM, Nikitenko NA, Gushchin VA, Smolyarchuk EA, Zyryanov SK, Borisevich SV, Naroditsky BS, Gintsburg AL; Gam-COVID-Vac Vaccine Trial Group. Logunov DY, et al. Among authors: shcheblyakov dv. Lancet. 2021 Feb 20;397(10275):671-681. doi: 10.1016/S0140-6736(21)00234-8. Epub 2021 Feb 2. Lancet. 2021. PMID: 33545094 Free PMC article. Clinical Trial.
Combined stimulation of Toll-like receptor 5 and NOD1 strongly potentiates activity of NF-κB, resulting in enhanced innate immune reactions and resistance to Salmonella enterica serovar Typhimurium infection.
Tukhvatulin AI, Gitlin II, Shcheblyakov DV, Artemicheva NM, Burdelya LG, Shmarov MM, Naroditsky BS, Gudkov AV, Gintsburg AL, Logunov DY. Tukhvatulin AI, et al. Among authors: shcheblyakov dv. Infect Immun. 2013 Oct;81(10):3855-64. doi: 10.1128/IAI.00525-13. Epub 2013 Jul 29. Infect Immun. 2013. PMID: 23897616 Free PMC article.
Targeting TLR-4 with a novel pharmaceutical grade plant derived agonist, Immunomax®, as a therapeutic strategy for metastatic breast cancer.
Ghochikyan A, Pichugin A, Bagaev A, Davtyan A, Hovakimyan A, Tukhvatulin A, Davtyan H, Shcheblyakov D, Logunov D, Chulkina M, Savilova A, Trofimov D, Nelson EL, Agadjanyan MG, Ataullakhanov RI. Ghochikyan A, et al. J Transl Med. 2014 Nov 29;12:322. doi: 10.1186/s12967-014-0322-y. J Transl Med. 2014. PMID: 25432242 Free PMC article.
Genetic Passive Immunization with Adenoviral Vector Expressing Chimeric Nanobody-Fc Molecules as Therapy for Genital Infection Caused by Mycoplasma hominis.
Burmistrova DA, Tillib SV, Shcheblyakov DV, Dolzhikova IV, Shcherbinin DN, Zubkova OV, Ivanova TI, Tukhvatulin AI, Shmarov MM, Logunov DY, Naroditsky BS, Gintsburg AL. Burmistrova DA, et al. Among authors: shcheblyakov dv. PLoS One. 2016 Mar 10;11(3):e0150958. doi: 10.1371/journal.pone.0150958. eCollection 2016. PLoS One. 2016. PMID: 26962869 Free PMC article.
Powerful Complex Immunoadjuvant Based on Synergistic Effect of Combined TLR4 and NOD2 Activation Significantly Enhances Magnitude of Humoral and Cellular Adaptive Immune Responses.
Tukhvatulin AI, Dzharullaeva AS, Tukhvatulina NM, Shcheblyakov DV, Shmarov MM, Dolzhikova IV, Stanhope-Baker P, Naroditsky BS, Gudkov AV, Logunov DY, Gintsburg AL. Tukhvatulin AI, et al. Among authors: shcheblyakov dv. PLoS One. 2016 May 17;11(5):e0155650. doi: 10.1371/journal.pone.0155650. eCollection 2016. PLoS One. 2016. PMID: 27187797 Free PMC article.
Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia.
Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Dzharullaeva AS, Tukhvatulina NM, Shcheblyakov DV, Shmarov MM, Tokarskaya EA, Simakova YV, Egorova DA, Scherbinin DN, Tutykhina IL, Lysenko AA, Kostarnoy AV, Gancheva PG, Ozharovskaya TA, Belugin BV, Kolobukhina LV, Pantyukhov VB, Syromyatnikova SI, Shatokhina IV, Sizikova TV, Rumyantseva IG, Andrus AF, Boyarskaya NV, Voytyuk AN, Babira VF, Volchikhina SV, Kutaev DA, Bel'skih AN, Zhdanov KV, Zakharenko SM, Borisevich SV, Logunov DY, Naroditsky BS, Gintsburg AL. Dolzhikova IV, et al. Among authors: shcheblyakov dv. Hum Vaccin Immunother. 2017 Mar 4;13(3):613-620. doi: 10.1080/21645515.2016.1238535. Epub 2017 Feb 2. Hum Vaccin Immunother. 2017. PMID: 28152326 Free PMC article. Clinical Trial.
Virus-Vectored Ebola Vaccines.
Dolzhikova IV, Tokarskaya EA, Dzharullaeva AS, Tukhvatulin AI, Shcheblyakov DV, Voronina OL, Syromyatnikova SI, Borisevich SV, Pantyukhov VB, Babira VF, Kolobukhina LV, Naroditsky BS, Logunov DY, Gintsburg AL. Dolzhikova IV, et al. Among authors: shcheblyakov dv. Acta Naturae. 2017 Jul-Sep;9(3):4-11. Acta Naturae. 2017. PMID: 29104771 Free PMC article.
Stimulation of Dectin-1 and Dectin-2 during Parenteral Immunization, but Not Mincle, Induces Secretory IgA in Intestinal Mucosa.
Dzharullaeva AS, Tukhvatulin AI, Erokhova AS, Bandelyuk AS, Polyakov NB, Solovyev AI, Nikitenko NA, Shcheblyakov DV, Naroditsky BS, Logunov DY, Gintsburg AL. Dzharullaeva AS, et al. Among authors: shcheblyakov dv. J Immunol Res. 2018 Mar 14;2018:3835720. doi: 10.1155/2018/3835720. eCollection 2018. J Immunol Res. 2018. PMID: 29725603 Free PMC article.
38 results